Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 503 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-fasting Clear all

Conditions: Healthy, Young Adults
Interventions: RLIC - 5 cycles, RLIC - 4 Cycles, RLIC - 3 Cycles, Sham conditioning, Balance training, Arm training, Sequence production training; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 2, Pre Diabetes
Interventions: Parkland Diabetes Detection Program (PDDP) Screening Invitation; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 500,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Transtibial Amputation, Peripheral Artery Disease, Diabetes Mellitus
Interventions: Error-augmentation gait training, Error-correction gait training, Supervised walking; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Richmond, Virginia

Conditions: Non-Small Cell Lung Cancer
Interventions: ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 7
States / cities: Fayetteville, Arkansas • Loma Linda, California • Indianapolis, Indiana + 4 more

Conditions: Cataract
Interventions: Printed Instructions with Phone Reminders, Sharp Health Companion App (CareKit); Behavioral
Lead sponsor: Sharp HealthCare; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes, Obesity
Interventions: Pre-study dietary and exercise instruction., Screening examination and oral glucose tolerance test, Euglycemic clamp, VO2max., Acute exercise bout, Percutaneous needle muscle biopsies; Behavioral · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 59 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Healthy
Interventions: Finasteride; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Fatty Liver
Interventions: possible liver biopsy and serum collection; Procedure
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Anaemia
Interventions: GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
Interventions: (R)-9bMS; Drug
Lead sponsor: TechnoGenesys, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Infertility
Interventions: Fast Track to Fertility Algorithmic Text Messaging Platform; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Diabetes
Interventions: Time restricted feeding; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Terbinafine HCl 250mg tablets, Lamisil® 250 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pancreatic Cancer Non-resectable
Interventions: Folfirinox, Stereotactic Body Radiation Therapy; Drug · Radiation
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Healthy Participants
Interventions: EE/LNG, Baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy
Interventions: Glimepiride 4 mg Tablets, AMARYL® 4 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer
Interventions: SOZO Device, DEXA Scan; Device
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Healthy
Interventions: Pravastatin; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound, Liver Function, Obesity, Liver Fibroses
Interventions: Insulin Resistance, Quality of Life Assessment, Liver Function Test, Radiologic features of NASH, Serologic features of NASH; Diagnostic Test · Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Obesity
Interventions: Detemir; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 31 Years to 60 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cardiometabolic Health
Interventions: Animal-Based Protein Smoothie, Plant-Based Protein Smoothie, Plant-Based Protein Smoothie with Leucine; Dietary Supplement
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Moderately Overweight Individuals
Interventions: calorie restriction; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 35 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
Interventions: Alpelisib 300 mg, Placebo, [1-13C] sodium acetate, [6,6-2H2] D-glucose, Mixed Meal Tolerance Test, Nestlé BOOST Plus; Drug · Diagnostic Test · Dietary Supplement
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes
Interventions: Intermittent energy restriction (IER), Time Restricted Eating (TRE); Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement

Increasing Uptake of EHR-enabled Population Health Outreach Strategies to Improve Diabetes Screening

Optimizing Gait Rehabilitation for Veterans With Non-traumatic Lower Limb Amputation

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Sharp Health Companion App for Cataract Surgery Preparation and Recovery

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions

Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver Biopsy

Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

Fast Track to Fertility

Time Restricted Feeding (4-hour Versus 6-hour) for Weight Loss in Obese Adults

Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions

Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

Glimepiride 4 mg Tablets Under Non-Fasting Conditions

Body Composition During Cancer Treatment

Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions

A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)

Insulin Detemir in Obesity Management

How Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses

Effect of Daily Calorie or Alternate-day Calorie Reductions on Risk for Cardiovascular Disease and Cancer

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Intermittent Fasting for the Treatment of Type 2 Diabetes Mellitus